Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study

Annals of Oncology

Volumn 18, Issue 3, 2007, Pages 461-467

  Bidoli, P ^a   Zilembo, N ^a   Cortinovis, D ^a   Mariani, L ^a   Isa, L ^b   Aitini, E ^b   Cullura D ^b   Pari, F ^b   Nova, P ^a   Mancin, M ^a   Formisano, B ^a   Bajetta, Emilio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Department of Oncology ^*  (Italy)

Author keywords

First line chemotherapy; NSCLC; Phase II study; Platinum analogs

Indexed keywords

CARBOPLATIN; DOCETAXEL; GEMCITABINE; OXALIPLATIN;

ADULT; AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EDEMA; FEMALE; FLU LIKE SYNDROME; HEMATOLOGIC DISEASE; HUMAN; INFECTION; INOPERABLE CANCER; ITALY; LEUKOPENIA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LUNG SURGERY; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PAIN; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; VEIN THROMBOSIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; ITALY; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; TAXOIDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 33847637698     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl415     Document Type: Article

References (31)

1. Crinò L, Scagliotti GV, Ricci S et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 1999; 17: 3522-3530.
2. Scagliotti GV, De Marinis F, Rinaldi M et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell-lung cancer. J Clin Oncol 2002; 20: 4285-4291.
3. Kelly K, Crowley J, Bunn PA Jr et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial. J Clin Oncol 2001; 19: 3210-3218.
4. Rosell R, Gatzemeier U, Betticher DC et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: A cooperative multinational trial. Ann Oncol 2002; 13: 1539-1549.
5. Le Chevalier T, Scagliotti GV, Natale R et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: A meta-analysis of survival outcomes. Lung Cancer 2005; 47: 69-80.
6. Cosaert J, Quoix E. Platinum drugs in the treatment of non-small-cell lung cancer. Br J Cancer 2002; 87: 825-833.
7. Rudd RM, Gower NH, Spiro SG et al. Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-smallcell lung cancer: A phase III randomized study of the London Lung Cancer Group. J Clin Oncol 2005; 23: 142-153.
8. Treat J, Belani CP, Edelman MJ et al. A randomized phase III trial of gemcitabine (G) in combination with carboplatin (C) or paclitaxel (P) versus paclitaxel plus carboplatin in advanced (Stage IIIB, IV) Non-Small Cell Lung Cancer (NSCLC): Update of the Alpha Oncology trial (A1-99002L). ASCO Annual Meeting 2005 (Abstr 7025).
9. Hotta K, Matsuo K, Ueoka H et al. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004; 22: 3852-3859.
10. Zatloukal P, Petruzelka L, Zemanova M et al. Gemcitabine plus cisplatin vs GEM plus carboplatin in stage IIIb and IV non-small cell lung cancer: A phase III randomized trial. Lung Cancer 2003; 41: 321-331.
11. Faivre S, Le Chevalier T, Monnerat C et al. Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma. Ann Oncol 2002; 13: 1479-1489.
12. Franciosi V, Barbieri R, Aitini E et al. Gemcitabine and oxaliplatin: A safe and active regimen in poor prognosis advanced non-small cell lung cancer patients. Lung Cancer 2003; 41: 101-106.
13. Raymond E, Chaney SG, Taamma A et al. Oxaliplatin: A review of preclinical and clinical studies. Ann Oncol 1998; 9: 1053-1071.
14. Norton L, Day R. Potential innovations in scheduling of cancer chemotherapy. In DeVita VT, Hellman S, Rosemberg SA (eds): Important Advances in Oncology. Philadelphia: Lipincott Williams & Wilkins, 1991; 57-72.
15. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095-2103.
16. Iaffaioli RV, Tortoriello A, Facchini G et al. A phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non-small-cell lung cancer. J Clin Oncol 1999; 17: 921-926.
17. Bajetta E, Stani SC, De Candis D et al. Preclinical and clinical evaluation of four GEM plus carboplatin schedules as front-line treatment for stage IV non-smallcell lung cancer. Ann Oncol 2003; 14: 242-247.
18. Bidoli P, Stani SC, Mariani L et al. Phase I study of escalating doses of oxaliplatin in combination with fixed dose GEM in patients with non-small cell lung cancer. Lung Cancer 2004; 43: 203-208.
19. Pujol JL, Breton JL, Gervais R et al. Gemcitabine plus docetaxel for advanced or metastatic non-small cell lung cancer: Similar survival to cisplatin plus vinorelbine and less toxicity. Cancer Treat Rev 2005; 31: 571-576.
20. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48. Geneva, Switzerland: WHO 1979.
21. National Cancer Institute. Cancer Therapy Evaluation Program Common Toxicity Criteria, Version 2.0. [on-line] 1998; http://ctep.info.nih.gov/ reporting/index.html (1 and 7 November 2006, date last accessed)
22. Bryant J, Day R. Incorporating toxicity considerations into the design of two-stage phase II clinical trials. Biometrics 1995; 51: 1372-1383.
23. Cullen M. The development of gemcitabine and carboplatin in the treatment of non-small-cell lung cancer. Lung Cancer 2005; 50: S5-S7.
24. Ardizzoni A, Tiseo M, Boni L et al. CISCA (cisplatin vs. carboplatin) meta-analysis: An individual patient data meta-analysis comparing cisplatin versus carboplatinbased chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2006; 24: 366S (Abstr 7011).
25. Natale RB. Gemcitabine-containing regimens vs other in first-line treatment of NSCLC. Oncology 2004; 18: 27-31.
26. Thomas P, Robinet G, Gouva S et al. Randomized multicentric phase II study of carboplatin/gemcitabine and cisplatin/vinorelbine in advanced non-small cell lung cancer GFPC 99-01 study (Groupe francais de pneumo-cancerologie). Lung Cancer 2006; 51: 105-114.
27. Sederholm C, Hillerdal G, Lamberg K et al. Phase III trial of GEM plus carboplatin versus single-agent GEM in the treatment of locally advanced or metastatic non-small-cell lung cancer: The Swedish Lung Cancer Study Group. J Clin Oncol 2005; 23: 8380-8388.
28. Danson S, Middleton MR, O'Byrne KJ. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced non-small cell lung carcinoma. Cancer 2003; 98: 542-553.
29. Chiappori A, Simon G, Williams C et al. Phase II study of first-line sequential chemotherapy with GEM-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer. Oncology 2005; 68: 382-390.
30. Mazzanti P, Massacesi C, Rocchi MB et al. Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 2003; 41: 81-89.
31. Cappuzzo F, Novello S, De Marinis F et al. Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer. Br J Cancer 2005; 93: 29-34.